CO2022000804A2 - Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso - Google Patents

Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso

Info

Publication number
CO2022000804A2
CO2022000804A2 CONC2022/0000804A CO2022000804A CO2022000804A2 CO 2022000804 A2 CO2022000804 A2 CO 2022000804A2 CO 2022000804 A CO2022000804 A CO 2022000804A CO 2022000804 A2 CO2022000804 A2 CO 2022000804A2
Authority
CO
Colombia
Prior art keywords
binding proteins
eso
antigen
new york
cell carcinoma
Prior art date
Application number
CONC2022/0000804A
Other languages
English (en)
Spanish (es)
Inventor
David Dilillo
Frank Delfino
Jessica Kirshner
Kevin A Bray
Matthew C Franklin
Douglas Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74101175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2022000804(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2022000804A2 publication Critical patent/CO2022000804A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
CONC2022/0000804A 2019-07-03 2022-01-28 Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso CO2022000804A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962870232P 2019-07-03 2019-07-03
US202063020177P 2020-05-05 2020-05-05
US202063021826P 2020-05-08 2020-05-08
PCT/US2020/040642 WO2021003357A1 (en) 2019-07-03 2020-07-02 Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2022000804A2 true CO2022000804A2 (es) 2022-02-07

Family

ID=74101175

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000804A CO2022000804A2 (es) 2019-07-03 2022-01-28 Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso

Country Status (15)

Country Link
US (1) US12600783B2 (enExample)
EP (1) EP3993817A4 (enExample)
JP (2) JP7674278B2 (enExample)
KR (1) KR20220042137A (enExample)
CN (2) CN120248123A (enExample)
AU (1) AU2020301027B2 (enExample)
BR (1) BR112021026831A2 (enExample)
CA (1) CA3145857A1 (enExample)
CL (1) CL2021003550A1 (enExample)
CO (1) CO2022000804A2 (enExample)
IL (1) IL289573A (enExample)
MA (1) MA56468A (enExample)
MX (1) MX2022000081A (enExample)
PH (1) PH12021553306A1 (enExample)
WO (1) WO2021003357A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3175577A1 (en) 2020-03-30 2021-10-07 Mie University Bispecific antibody
WO2023176881A1 (ja) * 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
CN116970614A (zh) * 2022-12-29 2023-10-31 达冕疫苗(广州)有限公司 编码ny-eso-1的核糖核酸疫苗的组合物和方法
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
CN117843794B (zh) * 2023-12-01 2026-07-31 浙江大学 一种抗ny-eso-1的纳米抗体及其应用
WO2026006794A1 (en) * 2024-06-27 2026-01-02 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors and uses thereof
CN119161418B (zh) * 2024-08-30 2025-11-21 天津大学 一种结合ny-eso-1抗原的蛋白

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1061623A (zh) * 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
WO2003068800A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Isolated peptides which bind to hla molecules and uses thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
WO2005113595A2 (en) * 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
PL2457928T3 (pl) 2007-03-13 2017-10-31 Univ Zuerich Monoklonalne ludzkie przeciwciało swoiste względem nowotworu
WO2010106431A2 (en) 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof
WO2010141986A1 (en) * 2009-06-09 2010-12-16 Mabdesign Pty Ltd Novel antibodies and uses therefor
DK2971045T3 (da) * 2013-03-13 2019-09-16 Health Research Inc Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
CN104450615B (zh) * 2013-09-25 2020-12-15 深圳市北科生物科技有限公司 一种具有双特异性抗体的细胞CTL(BiAT)及其制备方法与应用
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US20160081314A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
IL281396B (en) 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
RU2018102526A (ru) 2015-06-24 2019-07-25 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
CN106729698A (zh) * 2015-11-25 2017-05-31 宁波美丽人生医药生物科技发展有限公司 NY-ESO-1有作为增强Art v1(wtArt)过敏原免疫反应分子佐剂的作用
US9994098B2 (en) 2015-12-23 2018-06-12 Xiaolin Ai Multimode electromechanical variable speed transmission apparatus with smooth mode shifting and method of controlling the same
JP2018013957A (ja) * 2016-07-21 2018-01-25 東芝テック株式会社 読取装置、サーバ装置、及びプログラム
AU2018207172B2 (en) * 2017-01-13 2023-10-12 Mink Therapeutics, Inc. T cell receptors that bind to NY-ESO-1 and methods of use thereof
CN110891977B (zh) * 2017-05-11 2023-10-27 温口特 特异性结合mrs的单克隆抗体
IL299348B2 (en) * 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
WO2019084538A1 (en) 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF
CN108383908A (zh) * 2018-02-05 2018-08-10 昆山百尔泰生物科技有限公司 识别人源ctla-4并阻断其功能的全人源单克隆抗体或抗体片段及其制备方法和用途
BR112022001194A2 (pt) 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
CA3175577A1 (en) * 2020-03-30 2021-10-07 Mie University Bispecific antibody
WO2021226063A1 (en) * 2020-05-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta

Also Published As

Publication number Publication date
CN114302733A (zh) 2022-04-08
EP3993817A4 (en) 2023-08-30
WO2021003357A1 (en) 2021-01-07
BR112021026831A2 (pt) 2022-02-22
CN120248123A (zh) 2025-07-04
KR20220042137A (ko) 2022-04-04
JP2022538475A (ja) 2022-09-02
AU2020301027B2 (en) 2026-07-30
US12600783B2 (en) 2026-04-14
MX2022000081A (es) 2022-04-27
AU2020301027A1 (en) 2022-02-24
US20220251215A1 (en) 2022-08-11
MA56468A (fr) 2022-05-11
PH12021553306A1 (en) 2022-08-01
EP3993817A1 (en) 2022-05-11
JP7674278B2 (ja) 2025-05-09
CA3145857A1 (en) 2021-01-07
IL289573A (en) 2022-03-01
JP2025156298A (ja) 2025-10-14
CN114302733B (zh) 2025-04-25
CL2021003550A1 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
CL2021003550A1 (es) Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso solicitudes relacionadas
MX2024014691A (es) Enlazadores de conjugacion mejorados
CO2022010422A2 (es) Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
CO2018011668A2 (es) Neoantígenos y métodos de su uso
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
SA519410284B1 (ar) Cd3 بنيات بولي ببتيد متعددة النوعية ذات ربط ل مقيد وطرق لاستخدامها
EA202190542A1 (ru) Сконструированные биспецифические белки
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CL2024001977A1 (es) Proteínas de unión al antígeno anti-virus de papiloma humano (hpv) y sus métodos de uso
MX2020007046A (es) Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales.
UY35964A (es) Anticuerpos humanos para pd?1
ECSP18073836A (es) Moléculas de unión a bcma y métodos de uso de las mismas
AR115702A1 (es) Moléculas agonistas biespecíficas de unión a antígeno 4-1bb
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
MX2020009116A (es) Proteinas triespecificas de union a antigenos.
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
AR120870A1 (es) Polipéptidos, complejos de proteínas y el método para obtenerlos
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
CO2022008314A2 (es) Anticuerpos anti–mertk y métodos de uso de los mismos
MX2024001067A (es) Composicion farmaceutica y uso.
ECSP18084153A (es) Anticuerpos anti-BASIGIN humanizados y uso de los mismos